CHENGDU, China – April , 2024 (XYZ Newswire) Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing patients in its Phase 2a clinical trial (NCT06363461) of topical TDM-18
CHENGDU – February 5, 2024Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed its Phase 2a clinical trial (NCT05802173) of TDM-105795 topical solution for Androgeneti
CHENGDU – December 04, 2023 (XYZ Newswire) Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed a Phase 1 clinical trial (NCT05525468) of TDM-180935 topical ointment f
Technoderma Medicines, Inc.is a clinical stage biopharmaceutical company.
The company's current core research and development programs include innovative drugs for the treatment of androgenic alopecia, eczema/atopic dermatitis, psoriasis and lupus. TDM-105795, the world's leading small-molecule drug candidate for the treatment of androgenic alopecia, has now completed 2a clinical trials. TDM-180935, a novel JAK1/TYK2 inhibitor for eczema/atopic dermatitis, also completed a Phase 1 clinical trial in December 2023 with favorable safety results.
